JP2024516079A - タンパク質及びその使用 - Google Patents

タンパク質及びその使用 Download PDF

Info

Publication number
JP2024516079A
JP2024516079A JP2023557729A JP2023557729A JP2024516079A JP 2024516079 A JP2024516079 A JP 2024516079A JP 2023557729 A JP2023557729 A JP 2023557729A JP 2023557729 A JP2023557729 A JP 2023557729A JP 2024516079 A JP2024516079 A JP 2024516079A
Authority
JP
Japan
Prior art keywords
seq
nos
protein
inflammatory
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557729A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516079A5 (https=
Inventor
コンスタンティン ルーカス，アレクサンダー
ロバート ジャコミン，ポール
マーガレット ライアン，ステファニー
ラッシャー，ローランド
Original Assignee
ジェームズ・クック・ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021900769A external-priority patent/AU2021900769A0/en
Application filed by ジェームズ・クック・ユニバーシティ filed Critical ジェームズ・クック・ユニバーシティ
Publication of JP2024516079A publication Critical patent/JP2024516079A/ja
Publication of JP2024516079A5 publication Critical patent/JP2024516079A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023557729A 2021-03-17 2022-03-17 タンパク質及びその使用 Pending JP2024516079A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2021900769 2021-03-17
AU2021900769A AU2021900769A0 (en) 2021-03-17 Proteins and uses thereof
AU2022900508A AU2022900508A0 (en) 2022-03-03 Proteins and uses thereof (2)
AU2022900508 2022-03-03
PCT/AU2022/050234 WO2022192955A1 (en) 2021-03-17 2022-03-17 Proteins and uses thereof

Publications (2)

Publication Number Publication Date
JP2024516079A true JP2024516079A (ja) 2024-04-12
JP2024516079A5 JP2024516079A5 (https=) 2025-03-26

Family

ID=83321840

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557729A Pending JP2024516079A (ja) 2021-03-17 2022-03-17 タンパク質及びその使用

Country Status (5)

Country Link
US (1) US20240174719A1 (https=)
EP (1) EP4308592A4 (https=)
JP (1) JP2024516079A (https=)
AU (1) AU2022236293A1 (https=)
WO (1) WO2022192955A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025170060A1 (ja) * 2024-02-08 2025-08-14 学校法人慈恵大学 急性肺障害治療薬

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042232A1 (en) * 2001-10-17 2005-02-24 Peter Hotez Hookworm vaccine
WO2010112836A1 (en) * 2009-03-31 2010-10-07 Moredun Research Institute Equine parasite detection
WO2015039189A1 (en) * 2013-09-18 2015-03-26 James Cook University Modified anti-inflammatory proteins and method of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042232A1 (en) * 2001-10-17 2005-02-24 Peter Hotez Hookworm vaccine
WO2010112836A1 (en) * 2009-03-31 2010-10-07 Moredun Research Institute Equine parasite detection
WO2015039189A1 (en) * 2013-09-18 2015-03-26 James Cook University Modified anti-inflammatory proteins and method of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACCESSION NO. Q8MU93, DATABASE UNIPROT[ONLINE], JPN6026001000, 1 October 2002 (2002-10-01), ISSN: 0005772847 *
BASAVARAJU SRIDHAR ET AL.: "Ac-FAR-1, a 20 kDa fatty acid- and retinol-binding protein secreted by adult Ancylostoma caninum hoo", MOLECULAR & BIOCHEMICAL PARASITOLOGY, vol. 126, JPN6026001001, 2003, pages 63 - 71, ISSN: 0005772846 *
NAVARRO SEVERINE ET AL.: "The hookworm pharmacopoeia for inflammatory diseases", INTERNATIONAL JOURNAL FOR PARASITOLOGY, vol. 43, JPN6026000999, 5 December 2012 (2012-12-05), pages 225 - 231, ISSN: 0005772848 *

Also Published As

Publication number Publication date
US20240174719A1 (en) 2024-05-30
EP4308592A4 (en) 2025-09-17
AU2022236293A1 (en) 2023-09-21
WO2022192955A1 (en) 2022-09-22
AU2022236293A9 (en) 2024-01-11
EP4308592A1 (en) 2024-01-24

Similar Documents

Publication Publication Date Title
US7304034B2 (en) Use of HMGB fragments as anti-inflammatory agents
Kokkola et al. Successful treatment of collagen‐induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity
US10981964B2 (en) Fusion protein comprising IL-4 and IL-10
CA2447576C (en) Use of hmg fragments as anti-inflammatory agents
JP5474009B2 (ja) Ｔｉｍ−３ポリペプチド
US20250163126A1 (en) Artificial synapses
US20040156851A1 (en) HMGB1 combination therapies
CN107454846B (zh) 修饰的肽及其治疗慢性炎性疾病的用途
US20240174719A1 (en) Proteins and uses thereof
EP1421218A2 (en) Model of autoimmune disease and methods for identifying agents against autoimmune disease
JP2004518430A (ja) ストレスタンパク質およびペプチドならびにその使用方法
JP2010527354A (ja) 免疫調節化合物によるアレルギー性疾患の治療
US20220204564A1 (en) Compositions and methods of inhibiting the binding of plasma igg autoantibodies to serotonin 2a receptor
US20190352341A1 (en) Modified peptides and their use for treating systemic lupus erythematosus
US11571462B2 (en) Engineered CCL20 locked dimer polypeptide
US20180237486A1 (en) An engineered ccl20 locked dimer polypeptide
CD Role of Th1 and Th17 CD4+ T cell subsets in the pathogenesis of experimental autoimmune encephalomyelitis
Martinez et al. of May 10, 2011

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260116

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260409